All In Biotech

Drug Trial Radar · NCT06786455

Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study

Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

Jan 23, 2025

Primary completion

Dec 3, 2025

Study completion Dec 3, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy of subcutaneous injection of SHR-1905 in adolescent asthmatic subjects - an open-label, single-dose Phase II clinical study

Conditions

  • Adolescent Asthma

Interventions

  • SHR-1905 InjectionDrug

    SHR-1905 Injection,medium dose, administered by subcutaneous injection;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK index: Serum SHR-1905 concentration。Time frame: Day 253
  2. PK index: Area under the plasma concentration versus time curve (AUC)。Time frame: Day 253
  3. PK index: Peak Plasma Concentration (Cmax)。Time frame: Day 253
  4. safety: Incidence and severity of any adverse events。Time frame: Day 253

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.